Drug profile · INN
indinavir sulfate
CRIXIVAN
indinavir sulfate (CRIXIVAN) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — indinavir sulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
indinavir sulfate (CRIXIVAN) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 protease inhibitor
Primary target: Human immunodeficiency virus type 1 protease
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is indinavir sulfate?
indinavir sulfate (CRIXIVAN) is a human immunodeficiency virus type 1 protease inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for indinavir sulfate?
CRIXIVAN is a marketed brand name for indinavir sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of indinavir sulfate?
indinavir sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.